Kennedy Institute of Ethics Journal 17 (4):321-350 (2007)
|Abstract||: This paper examines the nature of the harm-benefit tradeoff in early clinical research for interventions that involve remote possibility of direct benefit and likelihood of direct harms to research participants with fatal prognoses, by drawing on the example of gene transfer trials for glioblastoma multiforme. We argue that the appeal made by the component approach to clinical equipoise fails to account fully for the nature of the harm-benefit tradeoff—individual harm for social benefit—that would be required to justify such research. An analysis of what we label "collateral affective benefits," such as the experience of hope or exercise of altruism, shows that the existence of these motivations reinforces rather than mitigates the necessity of justification by reference to social benefit. Evaluations of social benefit must be taken seriously in the research ethics review process to avoid the exploitation of research participants' motivations of hope or altruism and to avoid the possibility of inadvertent exploitation of high-risk research participants and the harms that would associate with such exploitation.|
|Keywords||No keywords specified (fix it)|
|Through your library||Configure|
Similar books and articles
Janet Malek (2007). Understanding Risks and Benefits in Research on Reproductive Genetic Technologies. Journal of Medicine and Philosophy 32 (4):339 – 358.
Sara Vollmer & George Howard (2010). Statistical Power, the Belmont Report, and the Ethics of Clinical Trials. Science and Engineering Ethics 16 (4):675-691.
George Howard (2010). Statistical Power, the Belmont Report, and the Ethics of Clinical Trials. Science and Engineering Ethics 16 (4):675-691.
Kenneth V. Iserson (2007). Has Emergency Medicine Research Benefited Patients? An Ethical Question. Science and Engineering Ethics 13 (3).
David Wendler (2012). A New Justification for Pediatric Research Without the Potential for Clinical Benefit. American Journal of Bioethics 12 (1):23 - 31.
Lynn A. Jansen (2005). A Closer Look at the Bad Deal Trial: Beyond Clinical Equipoise. Hastings Center Report 35 (5):29-36.
Angela Ballantyne (2008). Benefits to Research Subjects in International Trials: Do They Reduce Exploitation or Increase Undue Inducement? Developing World Bioethics 8 (3):178-191.
Denis Collins (1989). Organizational Harm, Legal Condemnation and Stakeholder Retaliation: A Typology, Research Agenda and Application. Journal of Business Ethics 8 (1):1 - 13.
Eric Chwang (2010). Against Risk-Benefit Review of Prisoner Research. Bioethics 24 (1):14-22.
Sorry, there are not enough data points to plot this chart.
Added to index2009-01-28
Total downloads5 ( #160,483 of 549,514 )
Recent downloads (6 months)0
How can I increase my downloads?